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Common genetic variation may play an important role in altering chronic obstructive pulmonary
disease (COPD) risk. In Xuanwei, China, the COPD rate is more than twice the Chinese national
average, andCOPD is strongly associatedwith in-homecoal use. To identify genetic variation that
may be associated with COPD in a population with substantial in-home coal smoke exposures, we
evaluated 1261 single nucleotide polymorphisms (SNPs) in 380 candidate genes potentially rele-
vant for cancer and other human diseases in a population-based caseecontrol study in Xuanwei
(53 cases; 107 controls). PTEN was the most significantly associated gene with COPD in a min P
analysis using 20,000 permutations (PZ 0.00005). SNP-based analyses found that homozygote
variant carriers of PTEN rs701848 (ORTTZ 0.12, 95% CIZ 0.03e0.47) had a significant decreased
risk of COPD. PTEN, or phosphatase and tensin homolog, is an important regulator of cell cycle
progression and cellular survival via the AKTsignaling pathway. Our exploratory analysis suggests
that genetic variation in PTENmay be an important risk factor of COPD in Xuanwei. However, due
to the small sample size, additional studies are needed to evaluate these associations within
Xuanwei and other populations with coal smoke exposures.
Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by an inflammation of the lower airways and lung.ancer Institute, Division of Canc
Boulelvard, EPS 8118, MCS 7240,
h.gov (H.D. Hosgood III).
hed by Elsevier Ltd.By 2020, COPD is estimated to be the third most common
cause of death and fifth most common cause of disability in
the world.1 In-home solid fuel burning for heating and
cooking, to which 3 billion people are exposed worldwide,2er Epidemiology and Genetics, Occupational and Environmental
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PTEN and COPD 1867is one environmental exposure associated with COPD.3
Since family history of COPD is also a risk factor for COPD,
genetic variation and its interaction with environmental
exposures may contribute to COPD etiology.4
Xuanwei, China poses a unique opportunity to assess
COPD susceptibility in a population with substantial in-
home coal smoke exposure. The primary source of indoor
air pollution in Xuanwei is smoke from burning coal for
heating and cooking. Xuanwei’s COPD rate is more than
twice the national average in China and is strongly associ-
ated with coal use.3,5 In Xuanwei, 90% of residents are
farmers with minimal industrial and automotive air pollu-
tion exposure.6 Nearly all women and few men cook, and
most men and nearly no women smoke tobacco.7
We hypothesized that a large-scale candidate gene
analysis would provide an insight into the etiology of COPD
in Xuanwei. Therefore, we analyzed 1261 single nucleotide
polymorphisms (SNPs) in 380 candidate genes using an Oligo
Pool (OPA) with an Illumina GoldenGate Assay. Candidate
SNPs were genotyped if they were potentially relevant for
cancer and other human diseases or had possible functional
significance, based on previously identified candidate
genes.Methods
This study population has been previously described.8
Briefly, all residents of Xuanwei, China from March 1995 to
March 1996 were eligible for inclusion in a lung cancer
population-based caseecontrol study, of which 122
enrolled. Controls were selected from the Xuanwei general
population using a household registration list and were
individually matched (nZ 122) to lung cancer cases by sex,
age (2 years), village, and type of fuel used for in-home
cooking and heating at time of interview. Controls with
previously diagnosed COPD were not eligible for this study.
At the same time, from March 1995 to March 1996, all newly
diagnosed chronic bronchitis and/or emphysema (COPD)
patients by the Xuanwei County Hospital, who had lived in
Xuanwei their entire lifetime, were also enrolled (nZ 53).
COPD patients were identified from those attending the
Xuanwei hospital for respiratory problems. Chronic bron-
chitis patients were diagnosed by the hospital if their
medical history included cough and sputum on most days
for at least 3 months over 2 consecutive years. Further,
emphysema patients were identified by clinical symptoms,
X-ray, and/or other hospital records. The participation rate
for controls and COPD cases was 100%. A standardized
questionnaire evaluating demographic information,
smoking history, family and personal medical history, fuel
use history, and other covariates was administered by
trained interviewers to cases in the hospital and to controls
in their homes. Smoking histories were determined by
questions on smoking status, age started smoking, amount
of tobacco smoked per day from cigarettes, and age quit
smoking, if applicable. Coal use histories were collected by
questions on type of fuel use, frequency of fuel use, and
amount of fuel used for all homes throughout the subject’s
lifetime.
Genotyping was performed on DNA extracted from
sputum samples via phenolechloroform extraction.9 Highthroughput genotyping was successful for 53 cases and 111
controls with an Oligo Pool (OPA) by the Illumina Gold-
enGate Assay (www.illumina.com) at the National Cancer
Institute’s Core Genotyping Facility (Gaithersburg, MD).
There was insufficient DNA available for 10 controls. Four
additional controls were excluded for missing demographic
data. Duplicate samples (nZ 18) of both cases and controls
were randomly distributed throughout the study plates to
ensure quality control and to determine the intra-subject
concordance rate for all assays (>98%). Initially, 1442 SNPs
from the SNP500Cancer (http://snp500cancer.nci.nih.gov)
database in over 400 genes were genotyped successfully.
Candidate SNPs were selected based on their potential
relevance to cancer and other human diseases or they had
possible functional significance, based on previously iden-
tified candidate genes. HardyeWeinberg equilibrium (HWE)
for each SNP was tested in controls with a Pearson c2 test or
a Fischer’s exact test if any of the cell counts were less
than five. Exclusion of 165 SNPs with low minor allele
frequency (<0.01) and 16 SNPs with substantial deviation
from HWE (p< 0.001) left 1261 SNPs in 380 genes for
analysis.
The association between each gene and COPD was
assessed by the min P test in MatLab, which assesses the
significance of the minimal p value in each gene using
a permutation-based resampling procedure (20,000
permutations) that takes into account the number of SNPs
genotyped in each gene region and their underlying linkage
disequilibrium structure.10 false discovery rates (FDRs)
were calculated to evaluate the significance of the
min P results.11 Unconditional logistic regression was used
to estimate the odds ratio (OR) and 95% confidence interval
(CI) for the association between COPD risk and each
SNP independently, using the homozygote of the common
allele as the reference group and adjusting for age
(<55 years, 55 years), sex, smoking (non-smokers, <25
pack-years, 25 pack-years), and lifetime coal
use (<130 tons, 130 tons). Dose effects for each SNP were
estimated by a linear trend test by coding the genotypes
based on the number of variant alleles present (0, 1, 2).
Finally, interactions between the dominant genetic models
for the PTEN SNPs and lifetime coal use (<130 tons,
130 tons), as well as smoking (non-smokers, <25 pack-
years, 25 pack-years), were tested on the multiplicative
scale, adjusting for age, sex, smoking, and coal exposure.
All statistical methods were performed using SAS (Cary,
NC), unless stated otherwise.Results
Cases and controls were similar in sex, smoking status, and
tons of coal used over the course of their lifetime, but not
in age (Table 1).
Gene-based min P analysis identified 22 genes to
be significantly associated with COPD risk (min P< 0.05)
(Table 2). After adjusting for multiple comparisons, PTENwas
the most significantly associated gene with COPD risk
(FDRZ 0.019). POLB (FDRZ 0.076) and ARNT (FDRZ 0.22)
were also highly associated with COPD risk.
SNP analyses found that both the PTEN SNPs that were
genotyped were associated with COPD risk (Table 3).
Table 1 Study participant characteristics of caseecontrol study in Xuanwei.
Cases Controls OR* 95% CI* p Value**
n % n %
Gender 0.78
Male 34 64.2 71 66.4
Female 19 35.8 36 33.6
Age (years) 0.05
<55 13 24.5 43 40.2
55 40 75.5 64 59.8
Smoking (pack-years) 0.34
Non-smokers 22 41.5 45 42.1 1.00 Reference
<25 11 20.8 32 29.9 1.12 0.28e4.39
25 20 37.7 30 28.0 1.82 0.48e6.90
Lifetime coal use (tons) 0.47
<130 29 54.7 65 60.7 1.00 Reference
130 24 45.3 42 39.3 1.02 0.89e1.18
* Odds ratios (OR) and 95% confidence intervals (CI) are adjusted for age (<55 years, 55 years) and sex.
** X2 test.
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95% CIZ 0.03e0.47) and rs1903858 (ORAAZ 0.13, 95%
CIZ 0.04e0.44) were associated with about a 9-fold
decreased COPD risk. Since PTEN rs701848 and rs1903858 are
in complete linkage disequilibrium and moderately corre-
lated (D0Z 1.0 and r2Z 0.78, respectively), they areTable 2 Summary of the global gene p-values, permutation te
p 0.05.
Gene # SNPs p value for most
significant SNP*
PTEN 2 <0.0001
POLB 3 0.00010
ARNT 9 0.00040
IFNGR1 2 0.0023
RGS5 1 0.0073
ROS1 7 0.0012
MX1 7 0.0020
AMACR 6 0.0026
CFH 5 0.0042
IL12A 1 0.018
TERF1 5 0.0052
SLC23A1 3 0.0084
BAX 1 0.027
NQO1 2 0.026
PARP1 6 0.0064
MBL2 9 0.0037
LIPC 10 0.0035
CAV1 3 0.012
SCUBE2 3 0.013
ESR1 6 0.0072
PLK1 1 0.043
XRCC3 2 0.023
* Adjusted for age (<55 years, 55 years), sex, smoking (non-sm
(<130 tons, 130 tons).likely reporters of the same causative variant. PTEN
rs701848 and rs1903858 did not interact significantly
with coal use or smoking; however, there was some
evidence that PTEN rs701848 and rs1903858 may play
an important role in COPD risk among heavy smokers
(Table 4).st, and false discovery rate for all genes with a permutation
Permutation p e value
for gene*
False discovery rate
0.0001 0.019
0.00040 0.076
0.0018 0.22
0.0070 0.58
0.0092 0.58
0.0098 0.58
0.015 0.58
0.016 0.58
0.020 0.58
0.022 0.58
0.026 0.58
0.027 0.58
0.031 0.58
0.031 0.58
0.032 0.58
0.033 0.58
0.036 0.58
0.041 0.58
0.044 0.58
0.047 0.58
0.047 0.58
0.048 0.58
okers, <25 pack-years, 25 pack-years), and lifetime coal use
Table 3 PTEN polymorphisms and COPD risk.
SNP Genotype Cases Controls OR* 95% CI* p
rs701848 CC 31 29
CT 19 53 0.31 0.14e0.67 0.0030
TT 3 22 0.12 0.03e0.47 0.0020
CTþ TT 22 75 0.25 0.12e0.53 0.00026
Trend 0.00021
rs1903858 GG 24 22
AG 23 55 0.32 0.14e0.71 0.0054
AA 4 20 0.13 0.04e0.44 0.0010
AGþ AA 27 84 0.25 0.12e0.55 0.00055
Trend 0.00031
* Odds ratios (OR) and 95% confidence intervals (CI) are adjusted for age (<55 years,55 years), sex, smoking (non-smokers, <25 pack-
years, 25 pack-years), and lifetime coal use(<130 tons, 130 tons).
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Through an exploratory gene-based analysis, 22 genes were
identified as significantly associated with COPD suscepti-
bility, of which PTEN was the most significant gene after
accounting for multiple comparisons. PTEN rs701848 and
rs1903858, which were moderately correlated, were asso-
ciated with a significantly decreased risk of COPD.
PTEN, or phosphatase and tensin homolog, is an important
regulator of cell cycle progression and cellular survival via the
AKT signaling pathway.12,13 In fact, PTEN deletion is the most
commonmechanismof inappropriateAKTactivation inhuman
malignancy.14 PTENnegatively regulates theAKTpathwayand
is essential to homeostatis.15,16 As such, AKT and PTEN
expression have been observed to be inversely correlated in
lung cancer tissue samples.17 While this is the first report, to
the best of our knowledge, of specific PTEN SNPs associated
with COPD, we previously reported the association between
PTEN rs1903858 and lung cancer risk, in our parallel study in
Xuanwei, which utilized the same controls.18 The inverse
relationship observed in our studies between COPD and lung
cancer and PTEN rs1903858 suggests that the variantmay play
an important role in respiratory diseases.
Smoke-induced mutations have been hypothesized to be
associated with chronic inflammation of the airways and
lung that accompanies COPD.19 PTEN is one such gene that
is frequently mutated or deleted in the epithelium of
smokers.20 In mice, PTEN expression plays a crucial role in
mediating airway inflammation and responsiveness forTable 4 PTEN polymorphisms and COPD risk, by smoking status
SNP Genotype Non-smokers <2
OR (95% CI)* OR
rs701848 GG 1.00 (reference) 1.0
GAþ AA 0.40 (0.13e1.23) 0.1
rs1903858 AA 1.00 (reference) 1.0
AGþGG 0.38 (0.11e1.26) 0.3
* Odds ratios (OR) and 95% confidence intervals (CI) are adjusted for
130 tons).asthma.21 Further, PTEN overexpression also reduced
airway hyperresponsiveness in mice.22
Although smoking is an established risk factor for COPD, it
was only slightly associatedwith increased risk of COPD in our
analyses. Our results are similar to a cohort study in Xuanwei,
which also observed comparable smoking habits between
cases and the general population.23 Similarly, our lung cancer
studies in Xuanwei find only a slight increased risk of lung
cancer associatedwith smoking.24 The relativelyweak effect
of smoking on respiratory diseases in Xuanwei may result
from the indoor air pollution levels attributed to smoky coal
combustion in overwhelming the effect of tobacco smoke.
Given that smoking is an established risk factor for COPD, and
that smoky coal use has been associated with COPD in the
cohort study in Xuanwei, it was important to explore the
interactions between the significant PTEN SNPs and these
important environmental risk factors, even though the
statistical power was limited (<10%).
One of the major strengths of our population-based
caseecontrol study is the high participation rates. Further,
our results are biologically plausible given that PTEN could
contribute to COPD. Since the small sample size may lead to
false positive and false negative findings,25 our findings
should be viewed as hypothesis-generating. However, we
adjusted the gene-based analyses for multiple comparisons
to minimize the possibility of spurious findings. Due to our
small sample size, we had limited power to detect modest
risks at low minor allele frequencies (MAFs); however, we
did have ample power (>80%) to detect risks of 2.0 and 2.5.
5 Pack-years 25 Pack-years p Interaction
(95% CI)* OR (95% CI)*
0 (reference) 1.00 (reference)
4 (0.01e1.43) 0.15 (0.04e0.51) 0.24
0 (reference) 1.00 (reference)
6 (0.05e2.52) 0.15 (0.04e0.55) 0.35
age (<55 years, 55 years), sex, and lifetime coal use(<130 tons,
1870 H.D. Hosgood III et al.for MAFs of 0.3 and 0.1, respectively. Specific SNP
associations should be cautiously interpreted until these
results are replicated, since SNP associations may be
attributed to another SNP in linkage disequilibrium.
Although the functionality of each SNP is not known, PTEN
rs701848 is likely to alter PTEN expression and/or function
provided that it is located in the 30-translational termina-
tion codon. Further limitations of our study pertain to
generalizability. As our analysis included only Asians, the
generalizability of our findings to other ethnic groups is
limited. The allelic frequency variation by ethnicity in
HapMap found that the T allele at rs701848 is only 56%
among individuals of Asian descent, compared to 81% for
African descent. Similarly, the A allele at rs1903858 is only
44% among individuals of Asian descent, compared to 73%
and 58% for European and African descent, respectively.
Finally, our findings may not generalize to all COPD cases
since disease degree of severity was not available for our
analysis; however, it is likely that our study population
consists of individuals with moderate to severe COPD as
they sought treatment for symptoms in a hospital setting.
While some controls may have had mild undiagnosed COPD,
this would have underestimated our results.
In summary, our findings provide evidence of genetic
variation that may be important to COPD susceptibility. Our
results implicate the cell cycle and apoptosis regulatory
AKT signaling pathway, particularly PTEN. Our results
should be viewed as exploratory until they are replicated in
larger studies.
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